Yes, Depakote (valproate), lithium, and Zyprexa (olanzapine) are all appropriate and FDA-approved treatments for bipolar disorder.
These three medications represent the cornerstone of bipolar disorder pharmacotherapy, with lithium, valproate, and atypical antipsychotics like olanzapine forming the standard first-line treatment approach for acute mania in bipolar I disorder 1.
FDA Approval Status
The regulatory framework clearly supports all three agents:
- Lithium: Approved for acute mania and maintenance therapy (down to age 12 years in pediatric populations) 1
- Valproate (Depakote): FDA-approved for acute mania in adults 1
- Olanzapine (Zyprexa): FDA-approved for acute mania in adults, maintenance therapy, and (when combined with fluoxetine) for bipolar depression 1, 2
Treatment Selection Algorithm
When choosing between these three medications, base your decision on the following hierarchy:
Choose Lithium When:
- Patient has positive family history for bipolar disorder
- Classic mania-depression-interval pattern present
- Few previous episodes or hospitalizations
- High suicide risk (lithium has unique anti-suicide properties)
- No significant medical comorbidities
- Seeking maintenance/prophylactic benefit for both manic AND depressive episodes 3, 4
Choose Valproate When:
- Multiple previous episodes or hospitalizations
- Psychiatric comorbidities present
- Rapid cycling pattern
- Mixed episodes (though evidence is limited)
- Patient cannot tolerate lithium's side effects 3, 5
Choose Olanzapine When:
- Acute psychotic mania present
- Need for rapid antimanic effect
- Maintenance therapy required
- Bipolar depression (especially combined with fluoxetine) 2, 6
Phase-Specific Efficacy
Critical distinction: These medications perform differently across illness phases:
Acute Mania
All three are effective first-line options. Combination therapy (olanzapine + lithium or valproate) demonstrates superior efficacy compared to monotherapy in patients partially responsive to mood stabilizers alone 7. Response rates with combination therapy reach 67.7% versus 44.7% with monotherapy alone.
Maintenance/Prophylaxis
Lithium demonstrates the longest duration of successful monotherapy 4. In population-based studies, 75% of lithium-treated patients experienced treatment failure by 2.05 years, compared to only 0.98 years for valproate and 1.13 years for olanzapine. This represents a clinically meaningful difference favoring lithium for long-term management.
Bipolar Depression
Neither lithium nor valproate alone are recommended for acute bipolar depression 1. Olanzapine combined with fluoxetine shows the strongest evidence for bipolar depression treatment 6, 8.
Combination Therapy Considerations
When monotherapy with lithium or valproate produces inadequate response, adding olanzapine is evidence-based and superior to continuing monotherapy 7. The combination improves Young Mania Rating Scale scores by an additional 4 points and increases response rates by 23% compared to mood stabilizer alone.
Common side effects with combination therapy include somnolence, dry mouth, weight gain, increased appetite, tremor, and slurred speech 2, 7.
Critical Safety Monitoring
For olanzapine specifically, mandatory monitoring includes:
- Fasting glucose at baseline and periodically (risk of hyperglycemia, ketoacidosis, death)
- Fasting lipid profiles at baseline and periodically
- Weight monitoring at each visit
- Complete blood count monitoring in first months (leukopenia/neutropenia risk) 2
Common pitfall: Clinicians often avoid lithium due to its monitoring requirements and side effect profile, but alternative treatments may necessitate polypharmacy sooner, potentially creating additive side effect burdens 4.
Age-Specific Considerations
In adolescents (ages 13-17), lithium remains the only FDA-approved agent for bipolar disorder in youth, though this approval was based historically on adult literature 1. When prescribing olanzapine or valproate to adolescents, consider the increased potential for weight gain and dyslipidemia compared to adults, which may lead clinicians to consider other drugs first 1, 2.
Hierarchical Ranking for Bipolar I Disorder
Based on the most recent comprehensive guidelines, the hierarchical ranking for first-line treatments considering impact across all illness phases is:
- Lithium (strongest maintenance data, anti-suicide effects)
- Quetiapine (effective across all phases)
- Divalproex/Valproate (strong antimanic, moderate maintenance)
- Olanzapine (strong antimanic and maintenance, concerns about metabolic effects)
- Other atypical antipsychotics (asenapine, aripiprazole, paliperidone, risperidone, cariprazine) 8
Bottom line: All three medications are appropriate, FDA-approved, and evidence-based for bipolar disorder treatment. Selection should be guided by illness phase, patient characteristics, prior treatment history, and side effect tolerance rather than arbitrary preference.